Clinical Trial Update: Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update reports inspiratory flow rates achieved by COPD patients using three inhaler devices (Breehaler, Ellipta, and Handihaler); resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pulmonary Disease, Chronic Obstructive (COPD) | Phase 4 | Status: COMPLETED | Results posted: 2018-06-26